An evaluation of the FDA Responder Endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials

Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety

(2012) William D Chey et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation

(2012) Satish Rao et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis

(2012) Rebecca M. Lovell et al.   Clinical Gastroenterology and Hepatology

Interpreting patient-reported outcome results: US FDA guidance and emerging methods

(2011) Lori D McLeod et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale

(2009) B. SPIEGEL et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Irritable Bowel Syndrome

(2008) Emeran A. Mayer   NEW ENGLAND JOURNAL OF MEDICINE